Law360, New York (May 29, 2012, 1:53 PM ET) -- A shareholder of Human Genome Sciences Inc. on Friday asked a Maryland state court to block the biotech company's efforts to derail a $2.59 billion takeover attempt by British drugmaker GlaxoSmithKline PLC.
Plaintiffs in a putative class action filed last month in Montgomery County court are now seeking a temporary restraining order that would kill a poison pill meant to deter GSK's advances.
Human Genome, which makes gene-targeting medicines, rejected GSK's offer in April as too low and on May 17 launched a shareholder-rights plan to...
Human Genome's Resistance To $2.6B GSK Offer Draws Fire
To view the full article, take a free trial now.
